Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Receives Three Positive Coverage Decisions for Veristrat

NEW YORK (GenomeWeb) – Biodesix said today that it has received positive coverage decisions for its Veristrat test from Humana, Medical Mutual of Ohio, and PreferredOne.

Veristrat, Biodesix's flagship product, is a blood-based proteomic test for assessing patient prognosis and predicting response to drug treatment in advanced NSCLC.

Humana, which covers 9.6 million members nationally, determined as of Aug. 25 that the test was a medically necessary benefit for patients with non-small cell lung cancer. Medical Mutual, which covers 1.6 million members in Ohio, and PreferredOne, which covers 285,000 members in Minnesota, determined the test would be covered as of Oct. 14 and Sept. 13, respectively.

With these decisions, the test is now covered for roughly 216 million people in the US. In April, BlueCross BlueShield of Florida and Health Care Services Corporation announced they would cover Veristrat for their members. And Horizon Blue Cross Blue Shield of New Jersey issued a positive coverage decision in July.